Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 55 % of short-term debt in 2024; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 19.9 to 14.6.
-
Busy address KBO
21 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL from Gent, company number BE0475471036, closed financial year 2024 with a result of € 156,990 after tax. For that financial year BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL recorded a gross margin of € 1.4 million and equity of € 586,742. Compared with financial year 2023, the result moved from € 65,528 to € 156,990. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 21, 2025.
€ 586,742
▲ 37% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 156,990
▲ 140% vs 2023
Profit after tax over the fiscal year.
€ 187,625
▼ 20% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 86,742.
People and assets in 2024
14.6
▼ 4.7 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 1.1 million
▼ 19% vs 2023
€ 76,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 217
▼ 56% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
€ 250,000
Loans from banks and other lenders, long and short.
€ 1.9 million
▲ 24% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 148,524
▼ 39% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 1,030,104 | € 1,801,167 | € 1,706,178 | € 1,395,393 | ▼ 18% |
| Profit after taxes | € -209,789 | € 291,274 | € 65,528 | € 156,990 | ▲ 140% |
| Equity | € 72,950 | € 364,224 | € 429,752 | € 586,742 | ▲ 37% |
| Total debts | € 2,537,152 | € 2,264,221 | € 2,903,295 | € 4,260,781 | ▲ 47% |
| Cash | € 944,232 | € 250,234 | € 233,521 | € 187,625 | ▼ 20% |
| Retained profit | € -427,050 | € -135,776 | € -70,248 | € 86,742 | ▲ € 156,990 |
| Bank debt | € 250,000 | € 250,000 | € 250,000 | € 250,000 | |
| Balance sheet total | € 2,610,101 | € 2,628,445 | € 3,333,047 | € 4,847,523 | ▲ 45% |
| Employees (FTE) | 17.1 | 19.9 | 19.3 | 14.6 | ▼ 4.7 |
Key figures of BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL?
What happened at BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 156,990 (▲ 140% vs 2023). filed late Source: NBB ↗
- A.I.P. NV became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 209,789 loss in 2021 to € 156,990 profit in 2024.
Paid € 1,216 in corporate taxes since 2021.
Best year ever: 2022, with € 291,274 profit.
On average € 95,600 of value added per employee in 2024.
A new publication or filing at BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL? We notify you, reason included.
Follow BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROLDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Advanced incubation platform comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROLBehind BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL is A.I.P. NV. The shares are held by Advanced incubation platform (91.6%).
Directors
According to the 2024 annual accounts
Director · represented by Hugo VAN HEUVERSWYN
since 2020
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rijvisschestraat 118 box 1
9052 Gent
Klaartestraat 16
9052 Gent
Active since 11 September 2001
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 21 companies are registered at this address.
All companies at this address →Advanced incubation platform same network
€ 867,263 gross margin · 2024
STAPLES BELGIUM
€ 676,401 gross margin · 2025
GROUP AIP
INTEGRA CAPITAL PARTNERS
€ 327,777 gross margin · 2024
INTEGRA FUND PRIVAK
+16 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0475.471.036
- VAT number
- BE 0475.471.036
- Registered office
- Rijvisschestraat 118 bus 1, 9052 Gent
- Names & denominations
- BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL · BIOMARIC
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 August 2001
- Peppol
- Active · Active since 31 Oct 2023
- Activities · NACE
Medische laboratoria
Activiteiten van medische beeldvorming en medische laboratoria
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van medische laboratoria
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied